Cargando…

Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer

BACKGROUND: Serum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC). METHODS: Immunohistochemistry (IHC) te...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Cuipeng, Duan, Yaru, Wang, Bofei, Shi, Jianxiang, Wang, Peng, Ye, Hua, Dai, Liping, Zhang, Jianying, Wang, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417125/
https://www.ncbi.nlm.nih.gov/pubmed/34489945
http://dx.doi.org/10.3389/fimmu.2021.698312
_version_ 1783748322548252672
author Qiu, Cuipeng
Duan, Yaru
Wang, Bofei
Shi, Jianxiang
Wang, Peng
Ye, Hua
Dai, Liping
Zhang, Jianying
Wang, Xiao
author_facet Qiu, Cuipeng
Duan, Yaru
Wang, Bofei
Shi, Jianxiang
Wang, Peng
Ye, Hua
Dai, Liping
Zhang, Jianying
Wang, Xiao
author_sort Qiu, Cuipeng
collection PubMed
description BACKGROUND: Serum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC). METHODS: Immunohistochemistry (IHC) test in tissue array containing 280 OC tissues, 20 adjacent tissues, and 8 normal ovarian tissues was performed to analyze the expression of PDLIM1 in tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the autoantibody to PDLIM1 in 545 sera samples from 182 patients with OC, 181 patients with ovarian benign diseases, and 182 healthy controls. RESULTS: The results of IHC indicated that 84.3% (236/280) OC tissues were positively stained with PDLIM1, while no positive staining was found in adjacent or normal ovarian tissues. The frequency of anti-PDLIM1 autoantibody was significantly higher in OC patients than that in healthy and ovarian benign controls in both training (n=122) and validation (n=423) sets. The area under the curves (AUCs) of anti-PDLIM1 autoantibody for discriminating OC from healthy controls were 0.765 in training set and 0.740 in validation set, and the AUC of anti-PDLIM1 autoantibody for discriminating OC from ovarian benign controls was 0.757 in validation set. Overall, it was able to distinguish 35.7% of OC, 40.6% of patients with early-stage, and 39.5% of patients with late-stage. When combined with CA125, the AUC increased to 0.846, and 79.2% of OC were detected, which is statistically higher than CA125 (61.7%) or anti-PDLIM1(35.7%) alone (p<0.001). Also, anti-PDLIM1 autoantibody could identify 15% (18/120) of patients that were negative with CA125 (CA125 <35 U/ml). CONCLUSIONS: The anti-PDLIM1 autoantibody response in OC patients was positively correlated with PDLIM1 high expression in OC tissues, suggesting that the autoantibody against PDLIM1 might have the potential to be a novel serological biomarker of OC, serving as a complementary measure of CA125, which could improve the power of OC detection.
format Online
Article
Text
id pubmed-8417125
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84171252021-09-05 Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer Qiu, Cuipeng Duan, Yaru Wang, Bofei Shi, Jianxiang Wang, Peng Ye, Hua Dai, Liping Zhang, Jianying Wang, Xiao Front Immunol Immunology BACKGROUND: Serum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC). METHODS: Immunohistochemistry (IHC) test in tissue array containing 280 OC tissues, 20 adjacent tissues, and 8 normal ovarian tissues was performed to analyze the expression of PDLIM1 in tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the autoantibody to PDLIM1 in 545 sera samples from 182 patients with OC, 181 patients with ovarian benign diseases, and 182 healthy controls. RESULTS: The results of IHC indicated that 84.3% (236/280) OC tissues were positively stained with PDLIM1, while no positive staining was found in adjacent or normal ovarian tissues. The frequency of anti-PDLIM1 autoantibody was significantly higher in OC patients than that in healthy and ovarian benign controls in both training (n=122) and validation (n=423) sets. The area under the curves (AUCs) of anti-PDLIM1 autoantibody for discriminating OC from healthy controls were 0.765 in training set and 0.740 in validation set, and the AUC of anti-PDLIM1 autoantibody for discriminating OC from ovarian benign controls was 0.757 in validation set. Overall, it was able to distinguish 35.7% of OC, 40.6% of patients with early-stage, and 39.5% of patients with late-stage. When combined with CA125, the AUC increased to 0.846, and 79.2% of OC were detected, which is statistically higher than CA125 (61.7%) or anti-PDLIM1(35.7%) alone (p<0.001). Also, anti-PDLIM1 autoantibody could identify 15% (18/120) of patients that were negative with CA125 (CA125 <35 U/ml). CONCLUSIONS: The anti-PDLIM1 autoantibody response in OC patients was positively correlated with PDLIM1 high expression in OC tissues, suggesting that the autoantibody against PDLIM1 might have the potential to be a novel serological biomarker of OC, serving as a complementary measure of CA125, which could improve the power of OC detection. Frontiers Media S.A. 2021-08-19 /pmc/articles/PMC8417125/ /pubmed/34489945 http://dx.doi.org/10.3389/fimmu.2021.698312 Text en Copyright © 2021 Qiu, Duan, Wang, Shi, Wang, Ye, Dai, Zhang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Qiu, Cuipeng
Duan, Yaru
Wang, Bofei
Shi, Jianxiang
Wang, Peng
Ye, Hua
Dai, Liping
Zhang, Jianying
Wang, Xiao
Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title_full Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title_fullStr Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title_full_unstemmed Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title_short Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
title_sort serum anti-pdlim1 autoantibody as diagnostic marker in ovarian cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417125/
https://www.ncbi.nlm.nih.gov/pubmed/34489945
http://dx.doi.org/10.3389/fimmu.2021.698312
work_keys_str_mv AT qiucuipeng serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT duanyaru serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT wangbofei serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT shijianxiang serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT wangpeng serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT yehua serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT dailiping serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT zhangjianying serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer
AT wangxiao serumantipdlim1autoantibodyasdiagnosticmarkerinovariancancer